Nanotechnology Now - News Story: My Top Four Emerging Micro-Cap Biotech Stocks

Home > News > My Top Four Emerging Micro-Cap Biotech Stocks

November 19th, 2007

My Top Four Emerging Micro-Cap Biotech Stocks

Abstract:
BioSante Pharma (BPAX) recently began trading on the Nasdaq under a new ticker in early November and the Company has recently achieved clarity from the FDA on the clinical development requirements for its low-dose testosterone transdermal gel treatment candidate for female sexual dysfunction called LibiGel. BioSante expects to launch a Phase 3 safety trial before year-end and also plans to conduct a second Phase 3 efficacy trial in early 2008. The cardiovascular safety study will involve 2,400 to 3,100 women with one year results sufficient to support a NDA filing (with a four year follow-up also required) for LibiGel along with the two Phase 3 efficacy studies, which will be shorter in duration and involve fewer women. Other recent events include the acquisition of Bradley Pharma (BDY) by privately held Nycomed. Bradley currently markets BioSante's lowest-approved dose transdermal estradiol gel for the treatment of hot flashes and the Nycomed acquisition could boost sales of Elestrin as part of a bigger company with a larger marketing budget. Finally, BioSante anticipates a licensing deal by year-end for its CaP nanotechnology in the area of cosmetic medicine as a dermal filler for the treatment of wrinkles and other applications.

Source:
seekingalpha.com

Bookmark: